Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 6Urinary Bladder Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Precancerous Conditions 1Papillomavirus Infections 1Non-melanomatous Skin Cancer 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Condylomata Acuminata 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Barrett Esophagus 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15Vaccines, Synthetic 10Papillomavirus Vaccines 7Vaccines 5Imiquimod 4Trichloroacetic Acid 3Gels 3human papillomavirus vaccine, L1 type 16, 18 2green tea extract polyphenone E 2Podophyllin 2Human Papillomavirus Recombinant Vaccine nonavalent 2Ethanol 2Duration of Therapy 2Cryotherapy 2Cantharidin 2ranpirnase 1polyphenon E 1nanocurcumin 1hecolin 1berdazimer sodium 1Zinc 1Viusid 1Vaccination 1VP-102 1Tuberculin 1Therapies, Investigational 1Tea 1Surgical Procedures, Operative 1PRA1 protein, Candida albicans 1Omiganan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Condylomata Acuminata × polyphenon E × Clear all
NCT01082302 2010-09-08

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

MediGene

Phase 4 Completed
43 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡